Tecentriq atezolizumab: Phase Ib data

Data from 23 evaluable patients with colorectal cancer in an open label, international Phase Ib trial showed that 800 mg IV atezolizumab every 2 weeks plus once-daily 20-60 mg Cotellic cobimetinib le...